Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBKQSZ)

Drug Name
TTP399 Drug Info
Indication
Disease Entry ICD 11 Status REF
Type 2 diabetes 5A11 Phase 2 [1]
Type-1 diabetes 5A10 Phase 1/2 [2]
Cross-matching ID
PubChem CID
54673176
TTD Drug ID
DMBKQSZ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucokinase (GCK) TTDLNGZ HXK4_HUMAN Activator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Glucokinase (GCK) DTT GCK 2.722 4.76 1.848 3.945
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 05 Endocrine, nutritional or metabolic disease
Disease Class ICD-11: 5A11 Type 2 diabetes mellitus
The Studied Tissue Liver tissue
The Studied Disease Type 2 diabetes [ICD-11:5A11]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glucokinase (GCK) DTT GCK 2.72E-01 0.76 0.52
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02405260) Add Glucokinase Activator to Target A1c (AGATA). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03335371) Evaluation of TTP399 in Patients With Type 1 Diabetes (SimpliciT1). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of vTv Therapeutics.